Management of high-risk retinoblastoma Journal Article


Authors: Chantada, G. L.; Dunkel, I. J.; Abramson, D. H.
Article Title: Management of high-risk retinoblastoma
Abstract: While intraocular retinoblastoma is highly curable and current treatments are aimed to preserve vision, once the disease has extended outside the eye, the chances of cure are significantly lower. Thus, extraocular dissemination is the leading cause of death caused by retinoblastoma worldwide. Its extent is estimated by imaging studies upon diagnosis, but they are useful only when there is a massive extraocular dissemination. Histopathological examination of the enucleated eye is used to evaluate microscopic invasion of the choroid, the optic nerve and the sclera, and postoperative therapy is decided upon this information. Since extraocular dissemination is uncommon in developed countries, there are few studies that provided evidence to support adjuvant therapy. When there is overt extraocular disease, children should be treated with neoadjuvant therapy followed by delayed enucleation and adjuvant therapy. The treatment of extraocular retinoblastoma and the controversies in its management are the subject of this review. © 2012 Expert Reviews Ltd.
Keywords: histopathology; review; cancer risk; treatment planning; cancer adjuvant therapy; chemotherapy; cancer staging; drug megadose; lymph node metastasis; antineoplastic agent; disease association; retinoblastoma; cancer invasion; minimal residual disease; enucleation; optic nerve; eye examination; bone marrow metastasis; pathology risk factors
Journal Title: Expert Review of Ophthalmology
Volume: 7
Issue: 1
ISSN: 1746-9899
Publisher: Informa Healthcare  
Date Published: 2012-02-01
Start Page: 61
End Page: 72
Language: English
DOI: 10.1586/eop.12.3
PROVIDER: scopus
DOI/URL:
Notes: --- - "Export Date: 1 March 2012" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ira J Dunkel
    371 Dunkel
  2. David H Abramson
    389 Abramson